Share：
Share this content in WeChat
X
[Chinese][PDF]68988
• Review •
Application of multimodal magnetic resonance imaging in the diagnosis of glioma cell proliferation
LIN Kun  CIDAN Wang-jiu  WANG Xiao-ming 

DOI:10.12015/issn.1674-8034.2017.06.015.


[Abstract] Brain glioma is a kind of malignant tumor with high incidence and poor prognosis, which lacks effective method of preoperative diagnosis, grading and prognosis evaluation. Multimodal magnetic resonance imaging is able to evaluate histopathological change of tumor based on structural MRI. Cell proliferation is key to tumor development, which is closely related to the clinical diagnosis, grading, treatment and prognosis. This article will review and discuss the progresses of multimodal magnetic resonance imaging in the evaluation of brain glioma cell proliferation.
[Keywords] Glioma；Magnetic resonance imaging；Cell proliferation；Diffusion weighted imaging；Magnetic resonance spectroscopy

LIN Kun Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China

CIDAN Wang-jiu Department of Radiology, People's Hospital of Tibet Autonomous Region, Lhasa 850000, China

WANG Xiao-ming* Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, China

*Correspondence to: Wang XM, E-mail: wangxm024@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This work was part of Clinical Capability Construction Project for Liaoning Provincial Hospitals No. LNCCC-B06-2014 Outstanding Scientific Fund of Shengjing Hospital No. 201402
Received  2016-12-21
Accepted  2017-02-21
DOI: 10.12015/issn.1674-8034.2017.06.015
DOI:10.12015/issn.1674-8034.2017.06.015.

[1]
Stylli SS, Luwor RB, Ware TM, et al. Mouse models of glioma. J Clin Neurosci, 2015, 22(4): 619-626.
[2]
Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther, 2015, 152: 63-82.
[3]
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol, 2016, 131(6): 803-820.
[4]
Arevalo-Perez J, Peck KK, Young RJ, et al. Dynamic contrastenhanced perfusion MRI and diffusion-weighted imaging in grading of gliomas. J Neurooncol, 2015, 25(5): 792-798.
[5]
Ryken TC, Parney I, Buatti J, et al. The role of radiotherapy in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol, 2015, 125(3): 551-583.
[6]
Cuccarini V, Erbetta A, Farinotti M, et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. J Neurooncol, 2016, 126(2): 279-288.
[7]
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007, 114(2): 97-109.
[8]
Jeong JW, Juhasz C, Mittal S, et al. Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas. Cancer Imaging, 2015, 15(1): 10.
[9]
Jiang RF, Jiang JJ, Zhao LY, et al. Diffusion kurtosis imaging can efficiently assess the glioma grade and cellular proliferation. Oncotarget, 2015, 6(39): 42380-42393.
[10]
Ren Y, Pang HP, Feng XY, et al. Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index. Neuroradiology, 2016, 58(2): 121-132.
[11]
Lotumolo A, Caivano R, Rabasco P, et al. Comparison between magnetic resonance spectroscopy and diffusion weighted imaging in the evaluation of gliomas response after treatment. Eur J Radiol, 2015, 84(12): 2597-2604.
[12]
Zhao J, Yang ZY, Luo BN, et al. Quantitative evaluation of diffusion and dynamic contrast-enhanced MR in tumor parenchyma and peritumoral area for distinction of brain tumors. PloS One, 2015, 10(9): e0138573.
[13]
Choi H, Paeng JC, Cheon GJ, et al. Correlation of 11C-methionine PET and diffusion-weighted MRI: is there a complementary diagnostic role for gliomas?. Nucl Med Commun, 2014, 35(7): 720-726.
[14]
Mabray MC, Cohen BA, Villanueva-Meyer JE, et al. Performance of apparent diffusion coefficient values and conventional MRI features in differentiating tumefactive demyelinating lesions from primary brain neoplasms. AJR Am J Roentgenol, 2015, 205(5): 1075-1085.
[15]
Togao O, Hiwatash A, Yamashita K, et al. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging. Eur Radiol, 2017, 27(2): 578-588.
[16]
Tonoyan AS, Pronin IN, Pitskhelauri DI, et al. A correlation between diffusion kurtosis imaging and the proliferative activity of brain glioma. Zh Vopr Neirokhir Im N N Burdenko, 2015, 79(6): 5-14.
[17]
Sui Y, Xiong Y, Jiang J, et al. Differentiation of Low- and High- Grade Gliomas Using High b-Value Diffusion Imaging with a Non-Gaussian Diffusion Model. AJNR American Journal of Neuroradiology, 2016, 37(9): 1643-1649.
[18]
Wang Q, Zhang H, Zhang JS, et al. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from lowgrade gliomas: a systematic review and meta-analysis. Eur Radiol, 2016, 26(8): 2670-2684.
[19]
Fudaba H, Shimomura T, Abe T, et al. Comparison of multiple parameters obtained on 3.0 T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol, 2014, 35(11): 2091-2098.
[20]
Shang HB, Zhao WG, Zhang WF. Preoperative assessment using multimodal functional magnetic resonance imaging techniques in patients with brain gliomas. Turk Neurosurg, 2012, 22(5): 558-565.
[21]
Fink JR, Carr RB, Matsusue E, et al. Comparison of 3.0 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging, 2012, 35(1): 56-63.
[22]
Anbarloui MR, Ghodsi SM, Khoshnevisan A, et al. Accuracy of magnetic resonance spectroscopy in distinction between radiation necrosis and recurrence of brain tumors. Iran J Neurol, 2015, 14(1): 29-34.
[23]
Lazovic J, Soto H, Piccioni D, et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol, 2012, 14(12): 1465-11472.
[24]
Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol, 2012, 107(1): 197-205.
[25]
Fuente MIDL, Young RJ, Rubel J, et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenasemutant glioma. Neuro Oncol, 2016, 18(2): 283-290.
[26]
Togao O, Yoshiura T, Keupp J, et al. Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades. Neuro Oncol, 2014, 16(3): 441-448.
[27]
Park JE, Kim HS, Park KJ, et al. Pre- and posttreatment glioma: comparison of amide proton transfer imaging with MR spectroscopy for biomarkers of tumor proliferation. Radiology, 2016, 278(2): 514-523.
[28]
Sakata A, Okada T, Yamamoto A, et al. Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neurooncol, 2015, 122(2): 339-348.
[29]
Ma B, Blakeley JO, Hong X, et al. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging, 2016, 44(2): 456-462.
[30]
Ginat DT, Mangla R, Yeaney G, et al. Correlation of diffusion and perfusion MRI with Ki-67 in high-grade meningiomas. AJR Am J Roentgenol, 2010, 195(6): 1391-1395.
[31]
Grabner G, Kiesel B, Wöhrer A, et al. Local image variance of 7.0 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. Eur Radiol, 2017, 27(4): 1556-1567.
[32]
马长顺, 吴静, 赵瑞华, 等. 高级别胶质瘤ADC值与Ki-67的相关性研究. 医学影像学杂志, 2013, 23(9): 1350-1353.
[33]
蔡林峰. 体素内不相干运动扩散加权成像在乳腺病变中的应用研究. 福州: 福建医科大学, 2014.

PREV CT and MRI diagnosis of parotid gland by mistake nonspecific adenocarcinoma: A case report
NEXT MRI evaluation of hepatic iron overload: recent advances
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn